Pharmacopsychiatry 2016; 49(04): 170-173
DOI: 10.1055/s-0042-104507
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Nucleus Accumbens Deep Brain Stimulation for Alcohol Addiction – Safety and Clinical Long-term Results of a Pilot Trial

Authors

  • U. J. Müller

    1   Department of Psychiatry, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • V. Sturm

    2   Department of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne
  • J. Voges

    3   Department of Stereotactic Neurosurgery, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • H.-J. Heinze

    4   Department of Neurology, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • I. Galazky

    4   Department of Neurology, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • L. Büntjen

    3   Department of Stereotactic Neurosurgery, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • M. Heldmann

    4   Department of Neurology, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • T. Frodl

    1   Department of Psychiatry, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • J. Steiner

    1   Department of Psychiatry, Otto-von-Guericke-University of Magdeburg, Magdeburg
  • B. Bogerts

    1   Department of Psychiatry, Otto-von-Guericke-University of Magdeburg, Magdeburg
Weitere Informationen

Publikationsverlauf

received 11. November 2015
revised 25. Februar 2016

accepted 29. Februar 2016

Publikationsdatum:
04. Mai 2016 (online)

Preview

Abstract

We report on the long-term clinical outcome (up to 8 years) of 5 patients who received deep brain stimulation (DBS) of the nucleus accumbens to treat their long-lasting and treatment-resistant alcohol addiction. All patients reported a complete absence of craving for alcohol; 2 patients remained abstinent for many years and 3 patients showed a marked reduction of alcohol consumption. No severe or long-standing side effects occurred. Therefore, DBS could be a promising, novel treatment option for severe alcohol addiction, but larger clinical trials are needed to further investigate the efficacy of DBS in addiction.